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Abstract
Appetite suppressants may be one strategy in the fight against obesity. This study evaluated whether Korean pine nut
free fatty acids (FFA) and triglycerides (TG) work as an appetite suppressant. Korean pine nut FFA were evaluated in
STC-1 cell culture for their ability to increase cholecystokinin (CCK-8) secretion vs. several other dietary fatty acids from
Italian stone pine nut fatty acids, oleic acid, linoleic acid, alpha-linolenic acid, and capric acid used as a control. At 50 μM
concentration, Korean pine nut FFA produced the greatest amount of CCK-8 release (493 pg/ml) relative to the other
fatty acids and control (46 pg/ml). A randomized, placebo-controlled, double-blind cross-over trial including 18
overweight post-menopausal women was performed. Subjects received capsules with 3 g Korean pine (Pinus koraiensis)
nut FFA, 3 g pine nut TG or 3 g placebo (olive oil) in combination with a light breakfast. At 0, 30, 60, 90, 120, 180 and
240 minutes the gut hormones cholecystokinin (CCK-8), glucagon like peptide-1 (GLP-1), peptide YY (PYY) and ghrelin,
and appetite sensations were measured. A wash-out period of one week separated each intervention day.
CCK-8 was higher 30 min after pine nut FFA and 60 min after pine nut TG when compared to placebo (p < 0.01). GLP-
1 was higher 60 min after pine nut FFA compared to placebo (p < 0.01). Over a period of 4 hours the total amount of
plasma CCK-8 was 60% higher after pine nut FFA and 22% higher after pine nut TG than after placebo (p < 0.01). For
GLP-1 this difference was 25% after pine nut FFA (P < 0.05). Ghrelin and PYY levels were not different between groups.
The appetite sensation "prospective food intake" was 36% lower after pine nut FFA relative to placebo (P < 0.05).
This study suggests that Korean pine nut may work as an appetite suppressant through an increasing effect on satiety
hormones and a reduced prospective food intake.
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Background
The global epidemic rise in obesity urgently requests new
strategies that are effective and easy to apply for the gen-
eral population. One potential strategy in the fight against
obesity is to reduce food intake via the use of natural
appetite suppressants. It has been shown that by overeat-
ing by as little as 50 to 100 kcal above energy balance it is
possible to gain at least one kilo a year [1] Thus, prevent-
ing the surplus in energy intake through natural appetite
suppressants may be useful in the prevention of obesity.
Food intake induces a complex feed back system regulat-
ing hunger and satiety. Intake, digestion and absorption
of food are all regulated by the nervous and the hormonal
system [2]. Several important gastro-intestinal hormones
exist of which some are known to be induced by fat intake.
A well-studied gut hormone is cholecystokinin (CCK-8)
that is released from duodenal enteroendocrine cells into
the blood stream in response to fatty acids or protein [3].
CCK-8 suppresses appetite, and higher concentrations of
CCK-8 produce larger appetite-suppressing events [4,5].
Other hormones that are important are glucagon like pep-
tide-1 (GLP-1), peptide YY (PYY) and ghrelin [6-9]. GLP-
1 and PYY are both produced in the ileum, induced by
passing fatty acids and carbohydrates. Higher concentra-
tions decrease appetite [6,9]. Ghrelin is produced by the
stomach in reaction to macronutrients [8]. It is the only
'satiety' hormone, which induces hunger, i.e. higher con-
centrations of ghrelin increase appetite. It is therefore
called the "hunger" hormone.
The satiety hormones increase after fat intake. Fat diges-
tion leads to formation of mono-glycerides and fatty
acids. Only fatty acids with chain lengths ≥ C12 are capa-
ble of releasing CCK-8 [10,11]. Long chain fatty acids are
more effective than medium chain fatty acids and poly-
unsaturated fatty acids are more effective than mono-
unsaturated fatty acids [12,13].
The purpose of this study was to evaluate the effects of
long chain poly unsaturated fatty acids from Korean pine
(Pinus koraiensis) nuts on satiety. Nut consumption has
been previously linked to satiety and pine nuts are widely
consumed in popular dishes and as condiments [14-17]
Oils are major constituents of nuts with the oil consisting
of as much as 60% of weight in pine nuts. Korean Pine nut
oil consists of more than 92% of poly- and mono-unsatu-
rated fatty acids (PUFAs and MUFAs) like pinolenic acid
(C18:3), linoleic acid (C18:2) and oleic acid (C18:1) [14].
Korean Pine nut oil is unique in that it contains approxi-
mately 15% of pinolenic acid (C18:3). Previous studies
on Korean pine nut oil have shown beneficial effects such
on lipoprotein metabolism and immune function but the
effects on satiety hormones have not been studied. [18].
The high composition of poly unsaturated fats and
unique concentration of pinolenic acid leads to the
hypothesis that Korean pine nut oil may be able reduce
appetite by an induction of satiety hormones. The present
study was designed to evaluate the effects of Korean pine
nut oil on in vitro CCK-8 release and if Korean Pine nut
oil is also capable of releasing satiety hormones in
humans and thereby having an effect on appetite sensa-
tions.
Results
Effects of Fatty acids on in vitro CCK release
The fatty acids evaluated in this study produced different
levels of CCK-8 release in the STC-1 cells (Figure 1).
Carpic acid produce a very small amount of CCK-8 release
(46 pg/ml) relative the the other fatty acids whereas
Korean pine nut fatty acids produced the largest amount
of CCK-8 release (493 pg/ml). The other fatty acids oleic
acid, linoleic acid, alpha-linolenic acid, and Italian stone
pine nut fatty acids produced 145 pg/ml, 138 pg/ml, 124
pg/ml, and 62 pg/ml respectively.
Effects of Korean pine nut oil on satiety hormones and 
subjective measures of satiety
The baseline characteristics of the 18 women that com-
pleted the study are presented in Table 1.
Log-transformation of the data was applied on CCK-8,
GLP-1, PYY and TG. CCK-8 release was higher after pine
nut FFA than after placebo at 30, 90, 120, and 180 min-
utes (Figure 2a; p-value: 0.0066; 0.0031; 0.0003; 0.0117;
respectively). CCK-8 release was also higher at 60 and 120
minutes for pine nut TG compared with placebo (p-value:
0.0068 and 0.0148). The CCK-8 AUC for pine nut FFA
was 60.3% higher than for placebo (p < 0.0001) and for
pine nut TG 22.0% higher than the CCK-8 AUC for pla-
cebo (p: 0.0189) (Table 2). Different response curves were
present for the three different treatments (p < 0.01). The
maximal concentration (= Cmax) of CCK-8 reached was
for pine nut FFA 2.0 ± 0.43 pmol/L, for pine nut TG 1.45
± 0.23 pmol/L and for placebo 1.08 ± 0.15 pmol/L (p-
value FFA vs placebo: 0.0001; p-value TG vs placebo:
0.0358; analysis based on log transformed data).
GLP-1 (Figure 2b) also showed overall different response
curves (p < 0.01) between treatments. The GLP-1 release
was higher after pine nut FFA then after the placebo at 60
(p-value: 0.0101). GLP-1 AUC was 25.1% higher after the
pine nut FFA than after placebo (p-value: 0.0343).
For ghrelin similar curves were seen after all three treat-
ments (Figure 2c) and no effect of pine nut FFA or pine
nut TG were observed.Lipids in Health and Disease 2008, 7:10 http://www.lipidworld.com/content/7/1/10
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At 60, 180 and 240 minutes the PYY concentrations after
pine nut FFA was higher than after placebo (Figure 2d).
The AUC was 16.2% higher for pine nut FFA versus pla-
cebo (p < 0.01).
The curves of blood glucose, insulin, serum TG and FFA
showed normal physiological responses to a carbohy-
drate-rich breakfast with no or only marginal differences
between the treatments (Figure 3a–3d). For glucose the
response differed slightly between pine nut FFA and pla-
cebo at 30, 60, 90 and 120 minutes (Figure 3a; p-values:
0.0077; 0.0021; <0.0001; 0.0044; respectively). At 90 and
120 minutes also the response after pine nut TG was
slightly different from placebo (p-value: 0.0004 and
0.0230). This difference was reflected in a slightly higher
AUC after pine nut FFA compared to placebo (Table 3).
The insulin response was lower after 30 and higher at 90
minutes after pine nut FFA compared to placebo (Figure
3b) (p < 0.05), but no differences were seen in the AUC.
The insulin response at 90 minutes was also higher for
pine nut TG compared to placebo (p < 0.05). The serum
FFA concentrations showed only minor differences at
three time points for pine nut FFA (at 30, 60 and 180 min-
utes; p-value: 0.0027; 0.0200; 0.0437; respectively) and
for the last time point for pine nut TG versus placebo (p-
value = 0.0210; Figure 3c), but no difference in AUC.
There were no differences between the treatments for
serum TG (Figure 3d).
Free fatty acids of Korean pine nut oil (Pinnothin), Italian stone pine nut and the fatty acids oleic acid, linoleic acid, alfa linolenic  acid were compared with respect to CCK release (ng/ml) from STC-1 cells after exposure for 1 hour to 50 uM of the fatty  acids Figure 1
Free fatty acids of Korean pine nut oil (Pinnothin), Italian stone pine nut and the fatty acids oleic acid, linoleic 
acid, alfa linolenic acid were compared with respect to CCK release (ng/ml) from STC-1 cells after exposure 
for 1 hour to 50 uM of the fatty acids. Capric acid served as a negative control.
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Table 1: Baseline characteristics of the subjects (n = 18)
Females Mean ± SEM
Age (years) 55 ± 1
Body weight (kg) 76.7 ± 1.6
Height (m) 1.68 ± 0.01
BMIa (kg/m2) 27.1 ± 0.4
Glucose (mmol/L) 5.3 ± 0.1
Insulin (mU/L) 5.8 ± 0.7
FSHb (IU/L) 101.9 ± 6.1
Oestradiol (pg/mL) 10.0 ± 0.0
aBMI = Body Mass Index
bFSH = Follicle Stimulating HormoneLipids in Health and Disease 2008, 7:10 http://www.lipidworld.com/content/7/1/10
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With respect to the appetite scores, no differences were
present between the treatments for hunger or desire to eat
(Figures 4a and 4c). Fullness was lower after pine nut TG
than after placebo at 30 minutes (p < 0.01), but this was
not the case for pine nut FFA (Figure 4b). The overall AUC
was however similar for the three treatments (Table 4).
Prospective food consumption was at 30 minutes 36%
lower for pine nut FFA compared to placebo (p-value:
0.0068) and, also pine nut TG seemed to be lower (p-
value = 0.0559; Figure 4d).
No adverse events were reported that were caused by the
treatments.
Discussion
This study shows for the first time that Korean pine nut
FFA and TG can increase satiety hormones and thereby
may affect prospective food intake.
Nut consumption is popular worldwide and has shown
many health benefits, particularly against cardiovascular
disease. [19,20] It has also been shown that nut consump-
tion is related to satiety and epidemiological evidence
links nut consumption inversely with body weight. [20]
Knowing that nuts can have effects on satiety, the purpose
of this trial was to evaluate the effects of oil from Korean
pine nuts and several dietary oils on in vitro and in vivo
satiety hormone release and feelings of satiety. It was
observed from the STC-1 cell culture study the fatty acids
from Korean pine nuts had the greatest ability to increase
CCK-8 release compared to the other fatty acids tested and
capric acid, the negative control. Korean pine nut FFA
were approximately 8-fold more potent in releasing CCK-
8 than Italian stone pine nut FFA, although they have sim-
ilar fatty acid profiles. However, Korean pine nut oil does
Table 2: Total area under the curve of the satiety hormones (n = 
18)
Hormone Treatment AUC totala p-valueb
CCK-8 Pine nut FFA 217.4 ± 28.1 < 0.0001c
Pine nut TG 165.4 ± 20.2
Placebo 135.6 ± 14.0
GLP-1 Pine nut FFA 2340.5 ± 268.3 0.0037c
Pine nut TG 1624.2 ± 130.3
Placebo 1871.3 ± 174.9
Ghrelin Pine nut FFA 241892 ± 14916 0.3966
Pine nut TG 248000 ± 13517
Placebo 246133 ± 14685
PYY Pine nut FFA 20581 ± 1419 0.0060c
Pine nut TG 17485 ± 1100
Placebo 17707 ± 918
aAll values are means ± SEM.
bDifferences between the three treatments were tested with a one-
way ANOVA.
cAnalysis based on log-transformed data.
Four hour postprandial responses of CCK-8 (1a), GLP-1  (1b), ghrelin (1c) and PYY (1d) in 18 overweight women Figure 2
Four hour postprandial responses of CCK-8 (1a), 
GLP-1 (1b), ghrelin (1c) and PYY (1d) in 18 over-
weight women. (closed circles) Pine nut FFA, (closed trian-
gles) pine nut TG, (open squares) placebo. Significant 
differences (p < 0.05) indicated by a: pine nut FFA versus pla-
cebo, b: pine nut TG versus placebo.
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contain slightly more long chain poly unsaturated fatty
acids (which contribute to CCK release) and is much
higher concentrated with pinolenic acid (15% vs. 1%).
The large discrepancy in pinolenic acid concentration may
be responsible for the large difference in CCK release
between Italian stone pine nut FFA and the other FFA
tested. Oleic, linoleic, and alpha-linolenic acid produced
similar amounts of CCK-8 release which were all approx-
imately 2-fold greater than Italian stone pine nut FFA. A
potential reason for this difference may be the specific
fatty acid concentration in the dosage, as the Italian stone
pine nut FFA was a 50 μM dose of a mixture of fatty acids
whereas the others was a single 50 μM dose of each FFA.
The fact that Korean pine nut FFA had the ability to signif-
icantly increase satiety hormones in vitro lead to the anal-
ysis in human subjects. The in vivo arm of the study was
performed in postmenopausal overweight women. The
results can not easily be applied to the total population
(men and women; lean and obese; pre-and postmenopau-
sal women) and therefore needs to be confirmed in other
studies as well. The subjects in this study were all 100%
compliant as the capsules were always taken in the pres-
ence of the study nurse. As there were no differences in
dinner consumption at home the evening prior to the test
day (data not shown) we assume that this did not affect
the hunger and satiety scores in the morning.
The effect of pine nut FFA on CCK-8 was stronger than for
pine nut TG. This is consistent with literature stating that
FFA are needed for induction of CCK-8 [21-23] From each
TG only two FFA will be hydrolyzed during digestion in
the gut. Therefore supplementation with pure FFA will
lead to a higher amount of FFA in the gut than pure TG
and thus to a higher effect on CCK-8. We could speculate
Table 3: Total area under the curve of blood parameters (n = 
18)
Parameter Treatment AUC totala p-valueb
Glucose Pine nut FFA 1386.9 ± 29.8 0.0012
Pine nut TG 1376.4 ± 27.3
Placebo 1329.8 ± 24.4
Insulin Pine nut FFA 4482.8 ± 414.7 0.3393
Pine nut TG 4492.7 ± 420.4
Placebo 4210.2 ± 369.7
Free fatty acids Pine nut FFA 135.1 ± 4.7 0.1849
Pine nut TG 144.3 ± 6.4
Placebo 139.8 ± 6.0
Triglycerides Pine nut FFA 324.0 ± 37.1 0.4787c
Pine nut TG 339.5 ± 43.2
Placebo 352.0 ± 41.8
aAll values are means ± SEM.
bOverall differences between the three treatments were tested with a 
one-way ANOVA.
cAnalysis based on log-transformed data.
Four hour postprandial responses of glucose (2a), insulin  (2b), serum free fatty acids (2c) and serum triglycerides (2d)  in 18 overweight women Figure 3
Four hour postprandial responses of glucose (2a), 
insulin (2b), serum free fatty acids (2c) and serum 
triglycerides (2d) in 18 overweight women. (closed cir-
cles) Pine nut FFA, (closed triangles) pine nut TG, (open 
squares) placebo. Significant differences (p < 0.05) indicated 
by a: pine nut FFA versus placebo, b: pine nut TG versus pla-
cebo.
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that 1.5 times more pine nut TG is required relative to
pine nut FFA to induce a similar increase in satiety hor-
mones.
GLP-1, like CCK-8, is known to be a potent regulator of
food intake; peripheral administration of GLP-1 reduces
energy intake in a dose dependent manner in both lean
and overweight human subjects [9]. Both CCK-8 and
GLP-1 release lead to a delay in gastric emptying, early
satiety and a decrease in food consumption [24]. They
serve as a negative feedback signal to limit the amount of
food consumed [25,26]. The effect of pine nut FFA and TG
on these hormones seen in this study suggests therefore
that they may influence appetite. As far as we know, no
other study has been performed so far to confirm these
results.
PYY release is known to be stimulated by lipids depending
on the fatty acid chain length (≥ C12) [6,27]. However, in
this study we could not demonstrate an effect of pine nut
FFA or TG on PYY, probably due to basal increased PYY
levels with pine nut FFA, although not statistically signifi-
cant. The shape of the PYY curve after pine nut FFA was
similar to the CCK-8 curve. This might be due to the effect
of these hormones on gastric emptying and gut transit
time slowing down the gastrointestinal passage of nutri-
ents [28,29]. It has been reported that at least in dogs
CCK-8 induction coincided with PYY release after fat
intake [30].
There was no difference in effect on ghrelin between pine
nut FFA or TG and placebo. This is in line with a recent
study by Poppitt and coworkers [31] showing that the
high fat meals and fatty acid saturation levels had no dif-
ferential effect on ghrelin levels in healthy men.
The overall glucose levels were slightly higher within 4
hours after pine nut FFA than after placebo. However, the
glucose levels stayed within normal ranges and returned
to levels identical to the placebo group within 3 hours. In
addition, only minor changes were seen in postprandial
insulin and serum FFA concentrations after the treat-
ments, but were not consistent over time.
Overall appetite sensations after the breakfast meal were
only marginally affected. Due to the smaller effects
present than expected and the high variability in VAS, as
is often seen in the subjective VAS scores [32,33], it seems
likely that this study was underpowered to demonstrate a
clear and significant effect on VAS scores.
The mechanism through which pine nut FFA and TG are
able to induce CCK-8 and GLP-1 remains unknown. The
formation or transport of chylomicrons might play a role.
It is known that fatty acids with chain lengths of <12 are
Mean four hour responses of hunger (3a), fullness (3b),  desire to eat (3c) and prospective food consumption (3d) in  18 overweight women Figure 4
Mean four hour responses of hunger (3a), fullness 
(3b), desire to eat (3c) and prospective food con-
sumption (3d) in 18 overweight women. (closed cir-
cles) Pine nut FFA, (closed triangles) pine nut TG, (open 
squares) placebo. Significant differences (p < 0.05) indicated 
by a: pine nut FFA versus placebo, b: pine nut TG versus pla-
cebo.
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transported from the enterocyte directly into the systemic
circulation via the portal vein, whereas fatty acids with
chain lengths of ≥ 12 are absorbed into the lymphatic cir-
culation as chylomicrons [34,35]. When chylomicron
transport was blocked in rats by specific inhibitors, fat-
induced suppression of food intake was also blocked
[36,37]. CCK-8 signaling pathways are closely related to
the transport of chylomicrons [38]. The fact that only fatty
acids with at least or more than 12 carbon atoms induce
CCK-8 is in favor of this mechanism. This suggests that
pine nut FFA and TG may particularly affect chylomicron
formation or transport and thereby influence release of
CCK-8. This fast CCK-8 release activates the CCKA recep-
tors of the afferent fibers of the nervus vagus sending sati-
ety signals to the brain which reduces gastric emptying.
This limits further food intake through an increased feel-
ing of satiety and a decreased appetite [21,24].
Conclusion
Pine nut FFA and pine nut TG supplementation seem to
increase the satiety-inducing hormones CCK and GLP-1
concentrations postprandially. This may lead to a reduced
prospective food intake suggesting that pine nut FFA and
TG may act as an appetite suppressant in overweight
women. Further human studies are needed to confirm
these effects and to evaluate effects on actual food intake
and body weight.
Materials and methods
Cholecystokinin Release Cell Assay
STC-1 cells were used in this study to evaluate the ability
of Korean Pine nut fatty acids and other dietary fatty acids
on CCK-8 satiety hormone release. Characterization of
the release of cholecystokinin was performed in a murine
neuroendocrine tumor cell line, STC-1 [39,40]. All fatty
acids were obtained from Lipid Nutrition, B.V.
(Wormerveer, The Netherlands). Fatty acids tested are
common to the diet and were Korean Pine Nut fatty acids
(monounsaturated-24%, polyunsaturated-64%, includ-
ing pinolenic acid-15%, saturated and trans-12%), Italian
Stone Pine nut fatty acids (monounsaturated-32%, poly-
unsaturated-59% including 1% pinolenic acid, saturated
and trans-9%) oleic acid, linoleic acid, alpha-linoleic acid,
and capric acid (C-10 fatty acid) negative control. Fatty
acids were diluted in cell culture media to a concentration
of 50 μM and added to cell culture. STC-1 cells were
grown in DMEM containing 2.5% fetal bovine serum,
15% horse serum, 100 U/ml penicillin, and 100 μg/ml
streptomycin. Cells were maintained at 37°C in 5% CO2
and 95% air atmosphere in RPMI 1640 supplemented
with 5% FCS, 2 mM glutamine, 100 U/ml penicillin and
50 μM streptomycin. Media was changed every 3–4 days.
Cells were routinely passaged upon reaching 70–80%
confluency by washing the cell layer with PBS and incu-
bating with a solution of trypsin-EDTA. Plating density of
2 × 106 cells by 75 cm2 is used for routine subculture. Cells
were trypsinized, plated in six-well culture plates, and
allowed to reach 60–80% confluence. On the day of the
experiment, cells were washed twice with media (without
serum) and then incubated with fatty acids in media for
60 minutes. After a 60 minute incubation period, media
were harvested, clarified by centrifugation to remove cell
debris and assayed for CCK concentrations using a CCK
immunoassay. All fatty acids were tested in at least two
separate experiments. 24 h before experiments, STC-1
cells were seeded into 6-well culture plates at 40 – 50%
confluency. On the day of the experiment, cells were
washed in 1 ml Krebs – Ringer bicarbonate buffer (pH
7,4) containing 0,2% (wt/vol) BSA (KRBB). STC1 cells
were pre- incubated for 15 min in 2 ml KRBB, before to be
incubated in a 2-ml amount of KRBB, with or without the
tested agents for 1 hour.
Table 4: Total area under the curve of the VAS scores (n = 18)
VAS score Treatment AUC totala p-valueb
Hunger Pine nut FFA 8211 ± 614 0.4697
Pine nut TG 8819 ± 886
Placebo 9100 ± 892
Fullness Pine nut FFA 7770 ± 832 0.5326
Pine nut TG 7273 ± 681
Placebo 7915 ± 633
Desire to eat Pine nut FFA 10039 ± 719 0.2241
Pine nut TG 10477 ± 896
Placebo 11252 ± 790
Prospective food consumption Pine nut FFA 9438 ± 703 0.2763
Pine nut TG 9372 ± 754
Placebo 10323 ± 687
aAll values are means ± SEM.
bOverall differences between the three treatments were tested with a one-way ANOVA.Lipids in Health and Disease 2008, 7:10 http://www.lipidworld.com/content/7/1/10
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At the end of incubation the supernatant was collected
and centrifuged at 1000 rpm for 5 min and immediately
frozen at -20°C for RIA
DNA content was measured by fluorometry after extrac-
tion of the culture cell contents.
CCK immunoassay
Media levels of CCK were measured using a standard
immunoassay protocol (Regul Pept 8:97–103) and an
antiserum that detects CCK. Media specimens were
assayed in duplicate. CCK immunoreactivity was meas-
ured using antiserum .39A (1/300,000) that cross reacts
100% with CCK-33 and CCK-8, 12% with sulfated gas-
trin-17, 5% with unsulfated gastrin-17, and less than
0.1% with unsulfated CCK-8 and gastrin-34. CCK-8 was
used as standard.
The Bolton-Hunter (Thr, Nle)-CCK-9 was labelled with
iodine 125 by the chloramine-T method and purified by
reverse-phase HPLC. The assay buffer used was 0.05 M
sodium phosphate pH 7.5.
Aliquots of 1 μl to 200 μl of supernatant were tested in
duplicate (day 0). The label was added at day 1 and char-
coal precipitation was performed 48 h later.
Subjects for in vivo CCK release
In total, 48 candidates were invited from the pool of vol-
unteers of TNO Quality of Life and came to the study
information session. After signing the informed consent
forms, 31 subjects received a health screening. This
included an interview on medical history, physical exam-
ination and routine laboratory tests on blood and urine,
sampled after an overnight fast. Subjects needed to meet
the following inclusion criteria: at least two years post-
menopausal with follicle stimulating hormone (FSH) >
40 IU/L and Oestradiol < 70 pg/mL; body mass index
(BMI) between 25–30 kg/m-2; regular eating pattern; no
metabolic, endocrine, intestinal disorder or a medical his-
tory related to the study outcome parameters; no smok-
ing; not sporting > 5 hours/week. Subjects were
postmenopausal to exclude a possible influence of the
menstrual cycle on appetite. Twenty-five subjects were eli-
gible for the study. Based on power calculations on appe-
tite scores it was found that for a power of 80%, 18
subjects should be included. Therefore, 18 subjects were
assigned to start the study and three were appointed as
reserve. At the first day of the study one subject dropped
out, because cannula insertion failed. She was immedi-
ately replaced by a reserve subject.
The study was approved by the Medical Ethics Committee
of the University Medical Centre of Utrecht (February 22,
2005) and conducted according to the ICH Guideline for
Good Clinical Practice, in March 2005.
Study design
The study was a randomised, placebo-controlled, double
blind cross-over trial. The cross-over design was balanced
for carry over. The participants were randomly assigned to
the intervention groups, with age and BMI equally distrib-
uted over the treatment groups.
Study treatment
Treatment consisted of either 3 g Korean pine nut FFA, 3 g
Korean pine nut TG or 3 g olive oil (placebo) which was
delivered by Lipid Nutrition B.V. (PinnoThin™, The Neth-
erlands). The treatments were delivered in the form of soft
gel capsules, with one capsule containing 750 mg. Sub-
jects were therefore provided each treatment with four
capsules to consume the total dose of 3 gram. The fatty
acid composition (%) of pine nut FFA, pine nut TG and
olive oil respectively was as follows: pinolenic acid 15.2%,
15.3%, 0.0%; linolenic acid 0.0%, 0.0%, 0.7%; linoleic
acid 45,1%, 45.6%, 5.6%; oleic acid 26.8%, 26.4%, 77.4
and saturated fatty acids 7.2%, 6.9%, 11.7%.
Study procedures
Subjects came to the metabolic ward of TNO Quality of
Life, Zeist, after an overnight fast. A cannula was inserted
in the forearm in an antecubital vein and a blood sample
was obtained (t = 0). The subjects were then provided with
a breakfast together with four treatment capsules. The
breakfast contained two slices of white bread with marma-
lade and without margarine. No additional fat besides the
capsules was provided. The subjects consumed the break-
fast and capsules together with one glass of water within
10 minutes. The composition of the breakfast was: energy
content: 954 kJ (228 kcal); protein: 5 grams (8.6 in energy
percentage (en%); fat: 1 gram (5.1 en%); carbohydrates:
49 grams (86.3 en%); fiber: 1.9 grams. After capsules and
breakfast were taken, blood was sampled at t = 30, 60, 90,
120, 180 and 240 minutes after start of breakfast. Appetite
feelings were scored each time just after blood collection
was performed. These procedures were followed for each
treatment on three test days, with a wash-out period of
one week between treatments.
Blood parameters
For blood lipids, glucose and insulin, blood was collected
using Vacutainer® tubes (10 mL). To obtain serum, the
tubes contained clot activator and were centrifuged for 10
minutes within 30 min after blood collection. The centri-
fuge was adjusted at 2,000 g and 4°C. After centrifugation
serum was removed. Samples were stored at -18°C, until
analysis. Glucose, TG and FFA were determined using
commercial test kits (Boehringer, Mannheim, Germany)
on a Hitachi 911 automatic analyser (Hitachi InstrumentLipids in Health and Disease 2008, 7:10 http://www.lipidworld.com/content/7/1/10
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Division, Ibaraki-ken, Japan). Insulin was determined
using an AIA-600 Immunoassay Analysator.
For satiety hormones blood was collected in a Vacutainer®
tube (10 ml) containing K3EDTA as coagulant and put on
ice water. Protease inhibitor Aprotinin (at a final concen-
tration of 500 KIU/ml of blood) and a DPP-IV inhibitor
(10 μl per ml of blood) (LINCO Research, Missouri, USA)
was immediately added to the blood. Subsequently, sam-
ples were centrifuged for 15 minutes at 2,000 g at 4°C,
within 30 minutes after collection and stored at < -70°C,
until analysis. Plasma CCK-8 concentrations were meas-
ured using an optimized and validated commercial
human RIA kit (Euro-Diagnostica, Malmö, Sweden). This
CCK-8 assay system has been optimized to reach a sensi-
tivity of 0.05 pmol/L with no cross-reactivity towards gas-
trin-17, and sulphated gastrin. The intra-assay CV was
8.9% at a concentration of 0.84 pmol/l and 4.9% at a con-
centration of 1.98 pmol/L. Plasma total GLP-1 concentra-
tions were measured using an optimized and validated
commercial human RIA kit (LINCO Research, Missouri,
USA). This assay has been optimized for quantitative
determination of all forms of GLP-1 (i.e. GLP-1(7–36)
amide, GLP-1(7–37), GLP-1(9–36) amide, GLP-1(9–37),
GLP-1(1–36) amide and GLP-1(1–37)) in plasma with a
lowest limit of detection of 2.0 pmol/L. The intra-assay CV
of GLP-1 was 13.3% at a concentration of 15.6 pmol/L
and 4.6% at a concentration of 31.9 pmol/L. Plasma total
PYY concentrations were measured using a commercially
available human RIA kit (LINCO Research, Missouri,
USA). This radioimmunnassay utilizes an antibody,
which recognizes both the 1–36 and 3–36 forms of
human PYY. The intra-assay CV of PYY was 2.7% at a con-
centration of 69.7 ng/L and 1.1% at a concentration of
116.4 ng/L.
Plasma total ghrelin concentrations were measured using
a commercially available human RIA kit (LINCO
Research, Missouri, USA). This total ghrelin assay meas-
ures both octanoylated ghrelin and des-octanoylated
ghrelin. The intra-assay CV of the total ghrelin RIA kit was
10% at a concentration of 1000 pg/ml, and 3.3% at a con-
centration of 1500 pg/ml.
Appetite scores
Appetite was evaluated using visual analogue scales (VAS)
for 'hunger', 'fullness', 'desire to eat' and 'prospective food
consumption' [32,33]. Visual analogue scales consisted of
150 mm horizontal lines, with each end expressing the
most positive or negative sensation (i.e. I am not hungry
at all/I am extremely hungry). Subjects drew a vertical line
on the horizontal line corresponding to their appetite sen-
sation. Visual analogue scales were scanned using Tele-
form Elite software (Teleform Elite, Version 6.2, Cardiff
Software Inc., California, USA). Distances on the visual
analogue scales were converted into scores between 0 and
100.
Statistical methods
Analysis of variance (one way ANOVA) was used to com-
pare the response curves of CCK-8, GLP-1, PYY, ghrelin,
glucose, insulin, serum TG and FFA and the VAS scores
after the three treatments. The total area under the curve
(AUC) was calculated for all parameters. The curve charac-
teristics, AUC and the maximal concentration (Cmax)
were statistically examined. The data were also analysed
on treatment effects per time point using one way
ANOVA. If the model assumptions were violated (non-
normality of the residuals), a log-transformation was
applied before the statistical analysis.
All data are presented as mean ± SEM. Statistical analysis
of the data was carried out using the SAS statistical soft-
ware package (SAS/STAT Version 8.2, SAS Institute, Cary,
NC). A p-value < 0.05 (two-sided) was considered statisti-
cally significant in all analyses.
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